Kristi Saavedra's Contact Details

Kristi Saavedra's Company Details

Respira Therapeutics, Inc.

Palo Alto, California, US • 19 Employees
Major Drugs

Respira Therapeutics is developing inhaled therapeutics for cardiopulmonary diseases that improve patient outcomes through enhanced drug targeting to the small airways of the lung. Respira combines proprietary dry-powder inhaler device technologies and advanced particle engineering-based inhaled drug formulation approaches to develop novel therapeutics that deliver the drug where it needs to be —in the lung and lung periphery, instead of in the oropharyngeal cavity. Respira’s lead product candidate, RT234-PAH, has received FDA Orphan Drug Designation for Pulmonary Arterial Hypertension and is in Phase 2 clinical trials as a first-in-class inhaled therapeutic for as-needed use to provide acute relief for the most commonly reported symptoms in PAH patients.